Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88(MUT)) WM patients, but shows lower activity in MYD88 wild-type (MYD88(WT)) disease. MYD88(WT) patients a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Hunter, Zachary R., Xu, Lian, Tsakmaklis, Nickolas, Demos, Maria G., Kofides, Amanda, Jimenez, Cristina, Chan, Gloria G., Chen, Jiaji, Liu, Xia, Munshi, Manit, Gustine, Joshua, Meid, Kirsten, Patterson, Christopher J., Yang, Guang, Dubeau, Toni, Samur, Mehmet K., Castillo, Jorge J., Anderson, Kenneth C., Munshi, Nikhil C., Treon, Steven P.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234368/
https://ncbi.nlm.nih.gov/pubmed/30401751
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022962
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares